Compare YMAT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMAT | IMRN |
|---|---|---|
| Founded | 1970 | 1994 |
| Country | Taiwan | Australia |
| Employees | 65 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 9.6M |
| IPO Year | N/A | 2016 |
| Metric | YMAT | IMRN |
|---|---|---|
| Price | $0.65 | $1.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.3M | 156.9K |
| Earning Date | 05-13-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.68 |
| 52 Week High | $6.45 | $2.38 |
| Indicator | YMAT | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 49.29 |
| Support Level | $0.32 | $0.72 |
| Resistance Level | $0.87 | $1.24 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 24.90 | 23.68 |
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.